-
CaMKII as a Therapeutic Target in Parkinson's Disease
… We anticipate that such interventions will help manage dyskinesias and other debilitating side effects associated … levodopa-based therapies. … Complications of Treatment … Dyskinesia … Tennessee … United States … Academia/Nonprofit …
-
Pathway Validation of a Biased Delta Opioid Receptor Ligand for PD Symptoms & Side Effects Relief
… of this class of molecule for therapeutic utility in PD. … Dyskinesia … Clinical Trial … Ontario … Canada … Target …
-
Dry Powder-Based Delivery of Intrapulmonary Levodopa as a Treatment for Motor Fluctuations in Parkinson's Disease
… to the development of both motor fluctuations and dyskinesias. As an adjunct to standard oral therapies, …
-
NR2B as a Therapeutic Target in Parkinson's Disease
… by the loss of striatal dopamine, as well as in the dyskinesias produced by repeated levodopa administration, we … progression of Parkinson’s Disease and in the moderation of dyskinesias associated with long-term levodopa …
-
Maintenance of Continuous Plasma Levodopa Levels through Continuous Subcutaneous Carbidopa Administration
… chronic levodopa therapy (such as motor fluctuations and dyskinesias). Current long-acting levodopa products or COMT … dopaminergic infusion therapies has shown that reducing dyskinesias and motor fluctuations can greatly improve …
-
LRRK2 Physiology in Parkinson's Disease
… between Parkinson’s patients and control subjects. … Dyskinesia … Clinical Trial … Illinois … United States … …